Pharmacogenetic and Antidepressant Treatment in Elderly

Not Applicable

Terminated

• Conditions: Depression
• Interventions: Biological: urine analysis

• Registration Number: NCT02856477
• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Brief Summary

The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients.

Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-11
• Primary Completion: 2016-04
• Study Completion: 2016-04
• Status Verified: 2016-08
• Study First Submitted: 2016-08-02
• Study First Submitted QC: 2016-08-02
• Study First Posted: 2016-08-04
• Last Update Submitted: 2016-08-04
• Last Update Posted: 2016-08-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• current major depressive disorder
• antidepressant treatment

Exclusion Criteria

• dextromethorphan contra-indication
• other psychiatric disorder
• kidney failure
• liver failure mini mental State Examination (MMSE)<18

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
adapted treatment	urine analysis	the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
non-adaptated treatment	urine analysis	the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis

Primary Outcome Measures

Name	Time	Method
patient remission	6 months	remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.

Trial Locations

Locations (1)

CHU Besancon; 🇫🇷 Besancon, Doubs, France